GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (FRA:AT2) » Definitions » Debt-to-Revenue

Atara Biotherapeutics (FRA:AT2) Debt-to-Revenue : 3.40 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Atara Biotherapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Atara Biotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €11.17 Mil. Atara Biotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €41.90 Mil. Atara Biotherapeutics's annualized Revenue for the quarter that ended in Dec. 2023 was €15.60 Mil. Atara Biotherapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 3.40.


Atara Biotherapeutics Debt-to-Revenue Historical Data

The historical data trend for Atara Biotherapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Debt-to-Revenue Chart

Atara Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A N/A 1.39 1.13 6.75

Atara Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 80.97 11.20 16.91 7.23 3.40

Competitive Comparison of Atara Biotherapeutics's Debt-to-Revenue

For the Biotechnology subindustry, Atara Biotherapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Debt-to-Revenue falls into.



Atara Biotherapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Atara Biotherapeutics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(11.168 + 41.9) / 7.861
=6.75

Atara Biotherapeutics's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(11.168 + 41.9) / 15.596
=3.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Atara Biotherapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics (FRA:AT2) Business Description

Traded in Other Exchanges
Address
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics (FRA:AT2) Headlines

No Headlines